Skip to main content
NKGen Biotech, Inc. (NKGN)
OTCMKTS · Delayed Price · Currency is USD
0.200
+0.010 (16.67%)
Mar 6, 2026, 9:30 AM EST

NKGen Biotech Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
 TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
 Mar '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
---0.080.43
Revenue Growth (YoY)
----81.92%-
Cost of Revenue
---0.020.03
Gross Profit
---0.060.4
Selling, General & Admin
14.7316.3114.087.667.59
Research & Development
9.2810.6615.6716.7514.67
Operating Expenses
24.0126.9729.7524.4122.26
Operating Income
-24.01-26.97-29.75-24.35-21.86
Interest Expense
-2.16-2.72-0.75-2.31-1.32
Other Non Operating Income (Expenses)
-13.4-30.62-24.80.08-0.08
EBT Excluding Unusual Items
-39.57-60.31-55.29-26.57-23.26
Merger & Restructuring Charges
---3.33--
Other Unusual Items
16.0716.07-24.33-0.18-
Pretax Income
-23.5-44.23-82.95-26.75-23.26
Income Tax Expense
0.050.050.010.010.01
Net Income
-23.55-44.29-82.95-26.75-23.27
Net Income to Common
-23.55-44.29-82.95-26.75-23.27
Shares Outstanding (Basic)
352915614
Shares Outstanding (Diluted)
352915614
Shares Change (YoY)
98.13%86.88%142.70%-55.40%-
EPS (Basic)
-0.68-1.54-5.38-4.21-1.63
EPS (Diluted)
-1.23-1.54-5.38-4.21-1.63
Free Cash Flow
-19.65-20.88-21.95-22.66-19.95
Free Cash Flow Per Share
-0.56-0.72-1.42-3.56-1.40
Gross Margin
---76.62%92.96%
Operating Margin
----31618.18%-5131.69%
Profit Margin
----34745.46%-5461.27%
Free Cash Flow Margin
----29425.97%-4683.33%
EBITDA
-22.78-25.79-28.54-23.14-20.73
D&A For EBITDA
1.231.181.21.211.13
EBIT
-24.01-26.97-29.75-24.35-21.86
Source: S&P Capital IQ. Standard template. Financial Sources.